...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Presentation at AACR Meeting April 10-15

 "If that's how it's going to go, I'd rather see Zenith sell for an "early bird special" price.  Give me $7 US today and I'll vote yes"

I'd vote yes too but if there's no early deal in site then get us listed on the Naz ASAP. 

Share
New Message
Please login to post a reply